The stock price of Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) has plunged by -2.09 when compared to previous closing price of 478.57, but the company has seen a -4.32% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2024-09-05 that Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX ) Morgan Stanley Conference Call September 5, 2024 11:30 AM ET Company Participants Reshma Kewalramani – President and CEO Charlie Wagner – CFO Conference Call Participants Terence Flynn – Morgan Stanley Terence Flynn Thanks for joining us, everybody. I’m Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley.
Is It Worth Investing in Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) Right Now?
VRTX has 36-month beta value of 0.42. Analysts have mixed views on the stock, with 12 analysts rating it as a “buy,” 10 as “overweight,” 5 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VRTX is 257.43M, and currently, short sellers hold a 1.72% ratio of that float. The average trading volume of VRTX on September 06, 2024 was 1.17M shares.
VRTX’s Market Performance
The stock of Vertex Pharmaceuticals, Inc. (VRTX) has seen a -4.32% decrease in the past week, with a -1.21% drop in the past month, and a -3.00% fall in the past quarter. The volatility ratio for the week is 2.42%, and the volatility levels for the past 30 days are at 1.92% for VRTX. The simple moving average for the last 20 days is -2.10% for VRTX stock, with a simple moving average of 8.21% for the last 200 days.
Analysts’ Opinion of VRTX
Many brokerage firms have already submitted their reports for VRTX stocks, with Barclays repeating the rating for VRTX by listing it as a “Equal Weight.” The predicted price for VRTX in the upcoming period, according to Barclays is $509 based on the research report published on August 05, 2024 of the current year 2024.
Redburn Atlantic, on the other hand, stated in their research note that they expect to see VRTX reach a price target of $545. The rating they have provided for VRTX stocks is “Buy” according to the report published on June 27th, 2024.
Evercore ISI gave a rating of “Outperform” to VRTX, setting the target price at $438 in the report published on April 11th of the current year.
VRTX Trading at -2.99% from the 50-Day Moving Average
After a stumble in the market that brought VRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.24% of loss for the given period.
Volatility was left at 1.92%, however, over the last 30 days, the volatility rate increased by 2.42%, as shares surge +0.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.11% lower at present.
During the last 5 trading sessions, VRTX fell by -4.32%, which changed the moving average for the period of 200-days by +36.61% in comparison to the 20-day moving average, which settled at $478.74. In addition, Vertex Pharmaceuticals, Inc. saw 15.16% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRTX starting from LEIDEN JEFFREY M, who sale 3,784 shares at the price of $499.00 back on Aug 30 ’24. After this action, LEIDEN JEFFREY M now owns 9,994 shares of Vertex Pharmaceuticals, Inc., valued at $1,888,216 using the latest closing price.
Bhatia Sangeeta N., the Director of Vertex Pharmaceuticals, Inc., sale 646 shares at $500.00 during a trade that took place back on Aug 30 ’24, which means that Bhatia Sangeeta N. is holding 4,435 shares at $323,000 based on the most recent closing price.
Stock Fundamentals for VRTX
Current profitability levels for the company are sitting at:
- -0.04 for the present operating margin
- 0.86 for the gross margin
The net margin for Vertex Pharmaceuticals, Inc. stands at -0.05. The total capital return value is set at -0.02. Equity return is now at value -3.24, with -2.42 for asset returns.
Based on Vertex Pharmaceuticals, Inc. (VRTX), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -1.01. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -9.38.
Currently, EBITDA for the company is 3.93 billion with net debt to EBITDA at 175.32. When we switch over and look at the enterprise to sales, we see a ratio of 11.36. The receivables turnover for the company is 6.23for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.52.
Conclusion
To put it simply, Vertex Pharmaceuticals, Inc. (VRTX) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
